
Properdin, Mouse, mAb E12
Monoclonal antibody E12 recognizes mouse properdin. The complement system is the first line of defense against pathogens and facilitates elimination of apoptotic and damaged cells. Positive regulator plasma protein properdin is critical for the alternative pathway of complement. It is a single-chain glycoprotein (ca 53kDa) consisting of six TSR sequences. In the blood it exists as a mixture of preferably head-to-tail trimers, but also dimers and tetramers. The protein is produced by leukocytes, like activated neutrophils monocytes and T-lymphocytes, but also by eg. stressed endothelial cells.
Properdin can both initiate and positively regulate the alternative pathway activity together with C3 and factors B, D, I and H. It binds to C3b where It stabilizes the labile C3bBb convertase which is deposited on immune complexes or foreign surfaces. Thereby enhancing the AP by stimulation of amplification of C3bBb-convertase formation in competition with catabolism of C3b by factor I, which uses factor H as a cofactor. The local amplification process leads to the creation of the alternative pathway C5 convertase, C3bBb3b, and initiates the terminal pathway of complement activation. The alternative pathway may account for ca 80% of the terminal pathway activity. Properdin has also been shown to directly limit factor H activity.
Recent studies show that properdin is also a pattern-recognition receptor (PRR) able to bind directly to microbial surfaces, apoptotic and necrotic cells (dangerous nonself and altered self). Inappropriate activation or dysregulation of the alternative pathway is a critical factor in development of several autoimmune conditions. Targets opsonized with properdin are labeled for clearance by scavenger cells, even without complement. This makes it a potential therapeutic target in diseases. Recent studies has shown renewed interest in the evaluating role of properdin in disease pathogenesis, like Asthma, arthritis, septic shock, AMD and C3 glomerulopathy.
IA: Antibody E12 can be used as capture and detection antibody.
FS: Antibody E12 abrogated alternative pathway activity and full inhibitory activity lasted at least 14 days (Ref.1).
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA